Clinical Efficacy and Safety of Brucea javanica Oil Emulsion Injection Combined with GP Regimen Treating Non-small Cell Lung Cancer: A Meta-analysis
- VernacularTitle:鸦胆子油乳注射液结合GP方案治疗非小细胞肺癌疗效和安全性的Meta分析
- Author:
Shumei LIU
1
;
Yifan ZHOU
;
Shuqin LV
;
Haitao YE
;
Fei TONG
Author Information
- Keywords: Brucea javanica oil emulsion injection; non-small cell lung cancer; chemotherapy; randomized controlled trials; meta-analysis
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2017;19(7):1245-1252
- CountryChina
- Language:Chinese
- Abstract: This study was aimed to systematically evaluate the clinical efficacy and safety of brucea javanica oil emulsion injection combined with gemcitabine plus cisplatin (GP) regimen in the treatment of non-small cell lung cancer.Literatures were retrieved from databases of CNKI,Wanfang database,VIP,CBM,Pubmed from the date of database establishment to March 2017.Journals on related fields were also manually searched.The randomized controlled trials (RCTs) of brucea javanica oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer were collected.The results showed that there were 12 included RCTs with 1 118 patients.The meta-analysis results showed that compared with single using of GP regimen,there were statistical significance in the partial remission rate [OR =1.59,95％ CI (1.23,2.05),P =0.000 4],the total remission rate [OR =1.72,95％ CI (1.33,2.22),P ＜ 0.000 1],the KPS (Karnofsky) score improvement [OR =2.59,95％ CI (1.96,3.43),P ＜ 0.000 01],the deterioration of KPS score [OR =0.33,95％ CI (0.25,0.46),P ＜ 0.000 01],the incidence of bone marrow suppression [OR =0.48,95％ CI (0.35,0.65),P ＜ 0.000 01],and the incidence of gastrointestinal adverse reactions [OR =0.46,95％ CI (0.23,0.91),P =0.03] by brucea javanica oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer.It was concluded that brucea javanica oil emulsion injection combined with GP regimen can increase clinical efficacy,decrease myelosuppression rate and gastrointestinal adverse reactions.
